Pilot Study Using Remote Monitoring with Locus Health iPhone App and Apple Watch for Adults Undergoing Outpatient Chemotherapy for Solid Tumors or Blood Cancers

What this Trial Is About

Researchers are evaluating the use of remote monitoring technology developed by Locus Health to track cancer patients undergoing outpatient chemotherapy. This pilot prospective clinical trial aims to assess the feasibility of using wearable devices like Apple Watches and the Locus Health iPhone app for early detection of chemotherapy-related toxicities. The study focuses on patient engagement with the technology, ease of use, and retention during treatment cycles for solid tumors and hematological malignancies. Participants are divided into three groups based on how frequently they receive symptom questions through the Locus Health app during their chemotherapy cycle. Cohort 1 receives daily queries from day 2 to the end of treatment, Cohort 2 receives daily queries from days 2 to 9 then every third day thereafter, and Cohort 3 receives daily queries for all symptoms from days 2 to 9, then every third day for pain only until the cycle ends. The study tracks adherence to using the Apple Watch and responding to app queries according to these schedules. During the study, participants are monitored for up to 120 days or until their chemotherapy regimen ends, whichever comes first. Researchers collect data on patient usage of the app and watch, symptom reporting, and user experience via questionnaires. The goal is to measure the feasibility of continuous remote monitoring and its ability to detect signs like fever or increased heart rate early, potentially leading to timely medical attention. Participants adherence and withdrawal rates are also tracked to assess the practicality of this approach in a real-world outpatient chemotherapy setting.

A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy